ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

03 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

15 May 2023 16:05:01 By Nasdaq GlobeNewswire

Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023

10 May 2023 07:30:01 By Nasdaq GlobeNewswire

Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023

09 May 2023 07:30:01 By Nasdaq GlobeNewswire

Zevra Announces Board of Directors and Leadership Changes

08 May 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy

03 May 2023 07:30:00 By Nasdaq GlobeNewswire

Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy

17 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy

04 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors

30 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative

17 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders

15 Mar 2023 07:26:12 By Nasdaq GlobeNewswire

Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates

07 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Present at 35th Annual Roth Conference

06 Mar 2023 07:30:00 By Nasdaq GlobeNewswire